Grant of options

RNS Number : 6540Y

MaxCyte, Inc.

10 September 2020

 

MaxCyte, Inc.

("MaxCyte" or the "Company")

Grant of options

Gaithersburg, Maryland - 10 September 2020:   MaxCyte (LSE: MXCT, MXCS), the global cell-based medicines and life sciences company, announces that 1,150,000 options of common stock in the Company ("Options") were granted to Amanda Murphy on 8 September 2020, as part of a pre-agreed arrangement upon Amanda's appointment as the Company's new Chief Finacial Officer.  

The Options vest ratably on a monthly basis over 48 months, have an exercise period of 10 years from date of grant, at which time they will expire, and have an exercise price equal to the closing price of MaxCyte's stock on 8 September 2020 (being the date of Amanda's appointment), of 330 pence.

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

1	Details of the person discharging managerial responsibilities/person closely associated
a)	Name	Amanda Murphy
2	Reason for the notification
a)	Position/status	Chief Financial Officer
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	MaxCyte, Inc.
b)	LEI	54930053YHXULRFCU991
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Grant of Options over Shares of Common Stock
b)	Identification Code	US57777K1060
c)	Nature of the transaction	Grant of options
d)	Price(s) and volume(s)	1,150,000 options at an exercise price of 330 pence per common stock
e)	Aggregated information - Aggregated volume - Price	N/A N/A N/A
f)	Date of the transaction	8 September 2020
g)	Place of the transaction	London Stock Exchange, AIM Market (XLON)

About MaxCyte

MaxCyte is a clinical-stage global cell-based therapies and life sciences company. As the inventors of the premier cell-engineering enabling technology, the Company helps bring the promise of next-generation cell and gene-editing therapies to life. The Company's technology is currently being deployed by leading drug developers worldwide, including all of the top ten global biopharmaceutical companies. MaxCyte licences have been granted for more than 120 cell therapy programmes, with more than 90 licensed for clinical use, and the Company has now entered into eleven clinical/commercial license partnerships with leading cell therapy and gene editing developers. MaxCyte was founded in 1998, is listed on the London Stock Exchange (AIM:MXCT, MXCL) and is headquartered in Gaithersburg, Maryland, US. For more information, visit    www.maxcyte.com .   

For further information, please contact:

MaxCyte Inc. Doug Doerfler, Chief Executive Officer Amanda Murphy, Chief Financial Officer [phone] Nominated Adviser and Joint Corporate Broker Panmure Gordon Emma Earl Freddy Crossley Corporate Broking Rupert Dearden [phone] Joint Corporate Broker Numis Securities Limited James Black Duncan Monteith [phone] Financial PR Adviser Consilium Strategic Communications Mary-Jane Elliott Chris Welsh Sukaina Virji [phone] [e-mail]

 

END

 

 

DSHLMMTTMTIBBMM